Sample at diagnosis | Source | ∆CT (DCK-GAPDH) | Therapy | Sample at relapse | Disease-free survival (months) | Source | ∆CT (DCK-GAPDH) | Difference in ∆CT between R and D samples |
---|---|---|---|---|---|---|---|---|
D1 | PBMC | 3.4 | A* | R1 | 12 | PBMC | 3.7 | +0.3 |
D2 | PE*** | 3.3 | A | R2 | 10 | PE*** | 5.3 | +2.0 |
D3 | FFPE | 0.1 | A | R3 | 5 | FFPE | 1.3 | +1.2 |
D4 | FFPE | 1.7 | B | R4 | 4 | FFPE | 3.5 | +1.8 |
D5 | PBMC | 1.4 | A | R5 | 7 | PBMC | 2.2 | +0.8 |
D6 | PBMC | 4.1 | B** | R6 | 3 | PBMC | 3.9 | −0.2 |
D7 | FFPE | 1.3 | B | R7 | 13 | FFPE | 3.5 | +2.2 |
D8 | FFPE | 2.0 | A | R8 | 25 | FFPE | 1.8 | −0.2 |
D9 | PBMC | 1.9 | B | R9 | N/A | PBMC | 3.3 | +1.4 |
D10 | PBMC | 2.3 | A | R10 | N/A | PBMC | 1.5 | −0.8 |